Viral and host characteristics of a child with perinatal HIV-1 following a prolonged period after ART cessation in the CHER trial

Avy Violari et al

The following abstract was presented as part of a poster dicussion session on viral reservoirs at the 9th IAS Conference on HIV Science (IAS 2017).

Background: In the 6-year CHER trial (2005-2011), HIV-infected infants were randomized to deferred antiretroviral therapy (ART) or early limited ART for 40 (ART-40W) or 96 (ART-96W) weeks; ART reinitiation was based on CD4 and clinical criteria. We describe a child, randomized to ART-40W in 2008, who on long term follow-up, maintains an undetectable viral load after 8.5 years off-ART.

Methods: Studies conducted to describe immunological and viral characteristics included: ultrasensitive qualitative nested and quantitative semi-nested PCR assay to assess HIV DNA reservoir; co-culture of CD4 cells with MOLT-4/CCR5 and CD8-depleted phytohaemagglutinin-activated lymphocytes to detect replication-competent virus.

Results: HIV diagnosis was confirmed by HIV-DNA PCR+ at age 32 days, and on days 39 and 60, VL was >750,000 and 151,000 copies/ml respectively. ART started at age 8.7 weeks and was interrupted at 40 weeks post randomisation. On ART, VL declined to < 50copies/ml at week 24 and was < 20 copies/ml post-interruption .During later follow-up 6-monthly VLwere also < 20copies/ml. At age 9.5 years, the child was clinically asymptomatic with CD4 802 cells/µl. Qualitative DNA PCR was negative. HIV-antibody by ELISA was negative but was weakly reactive to Gag p40 and p24 on Western blot; a weak Gag-specific CD4 T-cell response was detected by whole blood intracellular cytokine assay. Proviral DNA was positive by ultrasensitive nested (int) PCR and HIV DNA reservoir size was estimated at 2.2 copies/106 PBMCs by semi-nested quantitative (RT) assay. DNA sequencing of Gag confirmed subtype-C virus. No replication-competent virus was detected in culture supernatants by day 22 using p24 ELISA and ultrasensitive nested RT-PCR. All HLA loci were heterozygoous (A*30:02:01/66:01; B*08:01:01/44:03:01; C*04:01:01/07:01:01; DRB1*12:01:01/13:02:01; DPB1*01:01:01/18:01; B1*05:01:01/06:09:01). The KIRAA1 genotype included both full-length and truncated KIR2DS4. Immunophenotyping showed few CCR5-expressing CD4 T-cells (6.6%), low CCR5 density, low immune activation (HLA-DR, TIGIT), high PD-1expression and high % naive CD8 T-cells.

Conclusions: To our knowledge, this is the first case of sustained virological control from a randomized trial of ART interruption following early treatment of infants. Further investigation may expand our understanding of how the immune system controls HIV replication and inform future research strategies for ART interruption after early ART.
 

See all the presentations from this session, including slides and videos, here.

July 26, 2017
Year of publication
2017
Resource types
Conference materials
Countries
Tags
CHER trial, South Africa, HIV-infected infants, Children with HIV Early Antiretroviral Therapy (CHER), ART, ARVs, treatment, pediatric HIV, pediatric treatment, ART initiation, undetectable viral load, virological control, ART interruption, treatment interruption, functional cure, HIV cure research, viral reservoirs, IAS 2017, viral characteristics, host characteristics, perinatal infection, perinatally-infected children, perinatally acquired HIV infection, treatment cessation, ART cessation, HIV remission

Similar Resources

The Southern African HIV Clinicians Society’s biannual conference, held in Johannesburg, South Africa, from 24-27 October 2018, focused on clinical content for HIV and TB health care workers in the region and featured a wide range of topics…

BACKGROUND:

Attrition along the HIV care continuum slows gains in mitigating the South African HIV epidemic. Understanding population-level gaps in HIV identification, linkage, retention in care and viral suppression is critical to target programming.

Adolescents newly diagnosed with HIV need to be rapidly incorporated into HIV care networks to have the best chances of remaining in care in the long term, research from the United States published in the June 1st edition of the Journal of Acquired Immune Deficiency Syndromes shows.

The Accelerating Children’s HIV/AIDS Treatment (ACT) Initiative was a public-private partnership that expanded pediatric HIV services in nine sub-Saharan African countries from 2014-2016, providing treatment to more than 560,000 children living with HIV.

HIV eradication and remission research has largely taken place in high-income countries. In low- and middle-income countries (LMIC), there may be factors that have a substantial impact on the size of the latent HIV reservoir and the immunological response to infection.

Antiretroviral therapy (ART) that enables suppression of HIV replication has been successfully rolled out at large scale to HIV-positive patients in low-income and middle-income countries.

Many countries are working to reduce or eliminate mother-to-child transmission (MTCT) of HIV. Prevention efforts have been conceptualized as steps in a cascade but cascade completion rates during and after pregnancy are low.

In 2013, Uganda updated its prevention of maternal-to-child transmission of HIV program to Option B+, which requires that all HIV-infected pregnant and breastfeeding women be started on lifelong antiretroviral therapy (ART) regardless of CD4 count…

An essential first step in caring for HIV-infected children is accurate and early diagnosis of HIV, early HIV testing, prompt return of results, and rapid initiation of treatment.

Baylor-Malawi, with USAID funding, has developed a special JAIDS supplement featuring 11 articles which highlight lessons and best practices from the Accelerating Children’s HIV/AIDS Treatment (ACT) Initiative, a public-private partnership that expanded pediatric HIV services in nine sub-Saharan